Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENX-205 SAD and PET Study in Healthy Adults
NCT07253246Phase 1Completed
- Sponsor
- Engrail Therapeutics
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ENX-205 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 10 days. Started Mar 2025; status: completed.
02
Drugs
ENX-205
Beyond the preview
Go deeper on NCT07253246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253246.